Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for kne
0.000 (0.00%)
Oct 23 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.14 - 0.14
52 week 0.08 - 0.22
Open 0.14
Vol / Avg. 23,500.00/8,892.00
Mkt cap 10.82M
P/E     -
Div/yield     -
EPS -0.05
Shares 80.11M
Beta 0.63
Inst. own     -
Aug 16, 2017
Q2 2017 Kane Biotech Inc Earnings Release

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -770.14% -1041.33%
Operating margin -712.54% -994.66%
EBITD margin - -974.64%
Return on average assets -167.50% -154.27%
Return on average equity -398.98% -278.89%
CDP Score - -


162-196 Innovation Dr
+1-204-4531301 (Phone)
+1-204-8180374 (Fax)

Website links


Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation.

Officers and directors

Philip Renaud Independent Chairman of the Board
Mark William Ahrens-Townsend President, Chief Executive Officer
Ray Dupuis Chief Financial Officer
Arvind K. Joshi M.D. Independent Director
Mark H. Nawacki Independent Director